BioCentury | Feb 20, 2020
Politics, Policy & Law

Senate Democrats urge National Security Council to recruit pandemic expert for COVID-19 response

The absence of pandemic or global health expertise at the White House National Security Council and on the Trump administration's Coronavirus Task Force is prompting Senate Democrats to raise concerns about the quality of advice...
BioCentury | Feb 5, 2020
Regulation

Regulatory response: FDA authorizes emergency 2019-nCoV diagnostic, EMA activates emergency plan

FDA and EMA each unveiled measures Tuesday to combat the 2019-nCoV outbreak, with the U.S. agency issuing emergency use authorization for a diagnostic and its European counterpart activating its emerging health threats management plan. Both...
BC Extra | Jan 22, 2020
Preclinical News

Moderna, Novavax among biotechs working on novel virus -- but vaccine at least a year out

At least four groups have started to develop vaccines to protect against the 2019 Novel Coronavirus (2019-nCoV) that was first detected in Wuhan, China. Among companies working on a vaccine, Moderna Inc. (NASDAQ:MRNA) has partnered...
BioCentury | Nov 11, 2019
Emerging Company Profile

Mycovia tackling chronic infections with antifungal pipeline

Mycovia plans to bring a new generation of antifungals against CYP51 to market for difficult-to-treat indications, starting with chronic vaginal and nail infections. The company's lead product VT-1161 otesaconazole is in Phase III testing for...
BioCentury | Sep 27, 2019
Politics, Policy & Law

Trump administration to modernize flu vaccines via government buying power

The U.S. government is laying plans to harness its buying power and applied research capabilities to pull influenza vaccine development and manufacturing into the 21st century. The goals are to enhance protection against seasonal flu,...
BC Extra | Jun 6, 2019
Politics & Policy

New antibiotic treatments focus of reintroduced Senate bill

A bill that would advance research into new treatments for drug-resistant infections, the DISARM Act of 2019, was reintroduced in the Senate this week. The Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act ( S.1712...
BC Extra | May 16, 2019
Company News

Gilead defends Truvada pricing during House hearing

Chairman and CEO Daniel O'Day defended Gilead's pricing of HIV PrEP drug Truvada at a congressional hearing Thursday. Democrats led by House Oversight and Reform Committee Chair Elijah Cummings (D-Md.) pressed O'Day on the price...
BioCentury | Oct 6, 2018
Politics, Policy & Law

SUPPORTing FDA’s fight against opioids abuse

Legislation President Donald Trump is expected to sign soon gives FDA powers that are intended to blunt the opioid abuse epidemic and incentivize development of non-addictive pain treatments. The new authorities will give FDA tools...
BC Week In Review | Oct 5, 2018
Financial News

Trump signs spending bill with $2B NIH increase

President Donald Trump signed a FY19 appropriations bill into law on Sept. 28 that includes a $2 billion increase for NIH, bringing its budget to $39.1 billion. The legislation, H.R. 6157 , also includes a stopgap...
BC Extra | Sep 28, 2018
Politics & Policy

Trump signs spending bill with $2B NIH increase

President Donald Trump signed a FY19 appropriations bill into law Friday that includes a $2 billion increase for NIH, bringing its budget to $39.1 billion. The legislation, H.R. 6157 , also includes a stopgap provision that...
Items per page:
1 - 10 of 319
BioCentury | Feb 20, 2020
Politics, Policy & Law

Senate Democrats urge National Security Council to recruit pandemic expert for COVID-19 response

The absence of pandemic or global health expertise at the White House National Security Council and on the Trump administration's Coronavirus Task Force is prompting Senate Democrats to raise concerns about the quality of advice...
BioCentury | Feb 5, 2020
Regulation

Regulatory response: FDA authorizes emergency 2019-nCoV diagnostic, EMA activates emergency plan

FDA and EMA each unveiled measures Tuesday to combat the 2019-nCoV outbreak, with the U.S. agency issuing emergency use authorization for a diagnostic and its European counterpart activating its emerging health threats management plan. Both...
BC Extra | Jan 22, 2020
Preclinical News

Moderna, Novavax among biotechs working on novel virus -- but vaccine at least a year out

At least four groups have started to develop vaccines to protect against the 2019 Novel Coronavirus (2019-nCoV) that was first detected in Wuhan, China. Among companies working on a vaccine, Moderna Inc. (NASDAQ:MRNA) has partnered...
BioCentury | Nov 11, 2019
Emerging Company Profile

Mycovia tackling chronic infections with antifungal pipeline

Mycovia plans to bring a new generation of antifungals against CYP51 to market for difficult-to-treat indications, starting with chronic vaginal and nail infections. The company's lead product VT-1161 otesaconazole is in Phase III testing for...
BioCentury | Sep 27, 2019
Politics, Policy & Law

Trump administration to modernize flu vaccines via government buying power

The U.S. government is laying plans to harness its buying power and applied research capabilities to pull influenza vaccine development and manufacturing into the 21st century. The goals are to enhance protection against seasonal flu,...
BC Extra | Jun 6, 2019
Politics & Policy

New antibiotic treatments focus of reintroduced Senate bill

A bill that would advance research into new treatments for drug-resistant infections, the DISARM Act of 2019, was reintroduced in the Senate this week. The Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act ( S.1712...
BC Extra | May 16, 2019
Company News

Gilead defends Truvada pricing during House hearing

Chairman and CEO Daniel O'Day defended Gilead's pricing of HIV PrEP drug Truvada at a congressional hearing Thursday. Democrats led by House Oversight and Reform Committee Chair Elijah Cummings (D-Md.) pressed O'Day on the price...
BioCentury | Oct 6, 2018
Politics, Policy & Law

SUPPORTing FDA’s fight against opioids abuse

Legislation President Donald Trump is expected to sign soon gives FDA powers that are intended to blunt the opioid abuse epidemic and incentivize development of non-addictive pain treatments. The new authorities will give FDA tools...
BC Week In Review | Oct 5, 2018
Financial News

Trump signs spending bill with $2B NIH increase

President Donald Trump signed a FY19 appropriations bill into law on Sept. 28 that includes a $2 billion increase for NIH, bringing its budget to $39.1 billion. The legislation, H.R. 6157 , also includes a stopgap...
BC Extra | Sep 28, 2018
Politics & Policy

Trump signs spending bill with $2B NIH increase

President Donald Trump signed a FY19 appropriations bill into law Friday that includes a $2 billion increase for NIH, bringing its budget to $39.1 billion. The legislation, H.R. 6157 , also includes a stopgap provision that...
Items per page:
1 - 10 of 319